uniQure N.V.
QUREHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeuniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. Valued at $1.56B, QURE is a small-cap name in its sector. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding.
Market Cap
$1.56B
Beta
1.06
P/E (TTM)
—
P/E (Fwd)
-7.56
EPS (TTM)
$-4.03
EPS (Fwd)
$-2.97
ROE
-157.6%
ROA
-15.7%
Cash
$810.3M
Total Debt
$552.2M
Free CF
-$77.6M
52W Change
-67.0%
Annual Financials
Cash vs Debt
Where QURE stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, QURE finished 31.50% below its 150-day moving average ($32.41) and 25.08% below its 200-day moving average ($29.63). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is QURE overbought or oversold?
At the October 20, 2026 close, QURE's RSI(14) was 34.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $810.3M in cash comfortably exceeding the $552.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$77.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -157.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $106.5M (2022) to $16.1M (2025), a 85% decline worth watching.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing QURE.